RespireRx Pharmaceuticals Inc. (RSPI) financial statements (2020 and earlier)

Company profile

Business Address 126 VALLEY ROAD
GLEN ROCK, NJ 07452
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 000000
Cash and cash equivalents 000000
Prepaid expense 00000 
Deferred costs    0  
Other current assets      0
Other undisclosed current assets 000 00
Total current assets: 000000
Noncurrent Assets
Property, plant and equipment  (0)000 
Prepaid expense 00000 
Other undisclosed noncurrent assets  0    
Total noncurrent assets: 00000 
TOTAL ASSETS: 000000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 332122
Employee-related liabilities 102101
Interest and dividends payable    00 
Other undisclosed accounts payable and accrued liabilities 221120
Debt 000000
Due to related parties 111111
Other undisclosed current liabilities 212101
Total current liabilities: 656334
Noncurrent Liabilities
Total liabilities: 656334
Temporary equity, carrying amount   0   
Stockholders' equity
Stockholders' equity attributable to parent, including: (6)(4)(5)(3)(2)(4)
Preferred stock 00    
Common stock 000000
Additional paid in capital 159157152145139125
Accumulated deficit (164)(162)(158)(148)(142)(130)
Other undisclosed stockholders' equity attributable to parent   0010
Total stockholders' equity: (6)(4)(5)(3)(2)(4)
Other undisclosed liabilities and equity   (0)   
TOTAL LIABILITIES AND EQUITY: 000000

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues
(Revenue, Net)
    00 
Cost of revenue
(Financial Services Costs)
     (0) 
Gross profit:    00 
Operating expenses (2)(4)(8)(5)(4)(1)
Other undisclosed operating income     0 
Operating loss: (2)(4)(8)(5)(4)(1)
Nonoperating income (expense)
(Foreign Currency Transaction loss, before Tax)
 (0)     
Interest and debt expense (0)(0)(1)(1)(0)(0)
Net loss: (2)(4)(9)(6)(4)(1)
Other undisclosed net income (loss) attributable to parent (0)0(0)02(0)
Net loss attributable to parent: (3)(4)(9)(6)(3)(1)
Preferred stock dividends and other adjustments   (0)(0)(0) 
Other undisclosed net loss available to common stockholders, basic     (10) 
Net loss available to common stockholders, diluted: (3)(4)(9)(6)(13)(1)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (2)(4)(9)(6)(4)(1)
Comprehensive loss, net of tax, attributable to parent: (2)(4)(9)(6)(4)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: